XOMA/XOMA

$24.97

0.28%
-
1D1W1MYTD1YMAX

About XOMA

XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. Its royalty portfolio includes AFM13, AFM24, AB002 (proCase/E-WE thrombin), AB023 (xisomab, 3G3), AB054, AZD2936, AV-299 (ficlatuzumab), BAY1213790 (osocimab), CMP-001 (vidutolimod), Lysosomal Storage Disorders Enzymes, COM902, DAY101 (tovorafenib), vosaroxin, INCAGN1876, INCAGN1949, INCAGN02390, INCAGN2385, JNJ-63723283 (cetrelimab), MK-4830, MT-0169, CFZ533 (iscalimab), VPM087 (gevokizumab), NIS793, NIR178, G03-52-01, ebopiprant, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ358, RZ402, faricimab (faricimab-svoa), TAK-079 (mezagitamab), Aldoxorubicin, and Arimoclomol. The Company's subsidiaries include XOMA Technology Ltd., XOMA (US) LLC, and XOMA UK Limited.

Ticker

XOMA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Owen Hughes

Employees

12

Headquarters

Emeryville, United States

XOMA Metrics

BasicAdvanced
$286.05M
Market cap
-
P/E ratio
-$2.81
EPS
0.58
Beta
-
Dividend rate

What the Analysts think about XOMA

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 1 analysts.
196.36% upside
High $74.00
Low $74.00
$24.97
Current price
$74.00
Average price target

XOMA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-687.5% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$800K
-50%
Net income
$-5.5M
1.85%
Profit margin
-687.5%
103.7%

XOMA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 25%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.63
-$0.98
-$0.59
-$0.60
-
Expected
-$0.47
-$0.50
-$0.52
-$0.48
-$0.36
Surprise
34.04%
97.78%
14.34%
25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell XOMA stock

Buy or sell XOMA stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing